

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 August 2025 (21.08.2025)



(10) International Publication Number
WO 2025/174963 A1

(51) International Patent Classification:

A61K 40/11 (2025.01) C07K 16/28 (2006.01)
A61K 40/42 (2025.01)

(21) International Application Number:

PCT/US2025/015721

(22) International Filing Date:

13 February 2025 (13.02.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/554,420 16 February 2024 (16.02.2024) US

(71) Applicant: KITE PHARMA, INC. [US/US]; 2400 Broad-
way, Santa Monica, California 90404 (US).

(72) Inventors: FREITAS, Katherine A.; Kite Pharma, Inc., c/
o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City,
California 94404 (US). BODDU, Geetha; Kite Pharma,
Inc., c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster
City, California 94404 (US). KRISHNAMURTY, Chloe
Knights; Kite Pharma, Inc., c/o Gilead Sciences, Inc.,
333 Lakeside Drive, Foster City, California 94404 (US).
VIAUD, Sophie H.; Kite Pharma, Inc., c/o Gilead Sciences,
Inc., 333 Lakeside Drive, Foster City, California 94404
(US).

(74) Agent: SMITH, Michael J. et al.; Kite Pharma, Inc., c/o
Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, Cal-
ifornia 94404 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

(54) Title: SYSTEMS, METHODS, AND KITS FOR GENERATING AND ADMINISTERING ENGINEERED T CELLS AND
CD38 TARGETING COMPOUNDS AS A COMBINATION THERAPY




Figure 8

(57) Abstract: The present disclosure describes technologies for combination therapies using engineered T cells and a CD38 targeting compound. The technologies specifically address issues arising from combining therapeutics and generating and maximizing arising synergistic effects of the therapies while retaining and/or improving individually existing effects. The engineered T cells may include a CD38 expression modification offering protections against the CD38 targeting compound. The CD38 targeting compound may offer protection to the engineered T cells from NK cell-mediated rejection. Further, the combination therapies may target the same cells in a synergistic fashion. The technologies described herein may be embodied in methods of use, methods of manufacture, systems, engineered T cells, CD38 targeting compounds, kits, and other useful embodiments.

[Continued on next page]



WO 2025/174963 A1

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*